Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment

Neoplasia

Volumn 9, Issue 11, 2007, Pages 909-916

  Shafat, Itay ^a   Barak, Ayelet Ben ^b   Postovsky, Sergey ^b   Elhasid, Ronit ^b   Ilan, Neta ^a   Vlodavsky, Israel ^a   Ben Arush, Miriam Weyl ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b MEYER CHILDREN S HOSPITAL   (Israel)

Author keywords

Anticancer treatment; ELISA; Heparanase; Marker

Indexed keywords

ANTINEOPLASTIC AGENT; HEPARAN SULFATE; HEPARANASE; HEPARANASE ANTIBODY; N ACETYL BETA GLUCOSAMINIDASE; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER STAGING; CELL SURFACE; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; EWING SARCOMA; EXTRACELLULAR MATRIX; FEMALE; GERM CELL TUMOR; GLIOBLASTOMA; GLIOMA; HISTIOCYTOSIS X; HODGKIN DISEASE; HUMAN; INFANT; ISRAEL; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RHABDOMYOSARCOMA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 36048945359     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07673     Document Type: Article

References (46)

1. Dempsey LA, Brunn GJ, and Platt JL (2000). Heparanase, a potential regulator of cell - matrix interactions. Trends Biochem Sci 25, 349-351.
2. Parish CR, Freeman C, and Hulett MD (2001). Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471, M99-M108.
3. Vlodavsky I and Friedmann Y (2001). Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108, 341-347.
4. Edovitsky E, Elkin M, Zcharia E, Peretz T, and Vlodavsky I (2004). Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96, 1219-1230.
5. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, and Elkin M (2006). Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107, 3609-3616.
6. Roy M, Reiland J, Murry BP, Chouljenko V, Kousoulas KG, and Marchetti D (2005). Antisense-mediated suppression of heparanase gene inhibits melanoma cell invasion. Neoplasia 7, 253-262.
7. Ilan N, Elkin M, and Vlodavsky I (2006). Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38, 2018-2039.
8. Vlodavsky I, Ilan N, Naggi A, and Casu B (2007). Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13, 2057-2073.
9. Vreys V and David G (2007). Mammalian heparanase: what is the message? J Cell Mol Med 11, 427-452.
10. Ferro V, Hammond E, and Fairweather JK (2004). The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem 4, 693-702.
11. McKenzie EA (2007). Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151, 1-14.
12. Goldshmidt O, Yeikilis R, Mawasi N, Paizi M, Gan N, Ilan N, Pappo O, Vlodavsky I, and Spira G (2004). Heparanase expression during normal liver development and following partial hepatectomy. J Pathol 203, 594-602.
13. Katz A, Van-Dijk DJ, Aingorn H, Erman A, Davies M, Darmon D, Hurvitz H, and Vlodavsky I (2002). Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J 4, 996-1002.
14. Levidiotis V, Freeman C, Punler M, Martinello P, Creese B, Ferro V, van der Vlag J, Berden JH, Parish CR, and Power DA (2004). A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J Am Soc Nephrol 15, 2882-2892.
15. Levidiotis V, Freeman C, Tikellis C, Cooper ME, and Power DA (2004). Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol 15, 68-78.
16. Levidiotis V, Freeman C, Tikellis C, Cooper ME, and Power DA (2005). Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology 10, 167-173.
17. Levidiotis V, Kanellis J, Ierino FL, and Power DA (2001). Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int 60, 1287-1296.
18. Xiao Y, Kleeff J, Shi X, Buchler MW, and Friess H (2003). Heparanase expression in hepatocellular carcinoma and the cirrhotic liver. Hepatol Res 26, 192-198.
19. Shafat I, Zcharia E, Nisman B, Nadir Y, Nakhoul F, Vlodavsky I, and Ilan N (2006). An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 341, 958-963.
20. Ben Arush MW, Barak AB, Maurice S, and Livne E (2007). Serum VEGF as a significant marker of treatment response in Hodgkin lymphoma. Pediatr Hematol Oncol 24, 111-115.
21. Ben Arush MW, Schenzer P, Maurice S, Elhasid R, Postovsky S, Ben Barak A, Haimi M, Zeidman I, Hayari L, and Livne E (2005). Serum vascular endothelial growth factor as a significant marker of treatment response in pediatric malignancies. Pediatr Hematol Oncol 22, 513-524.
22. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky I, and Ilan N (2004). Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 117, 2249-2258.
23. Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, and Steinkuhler C (2004). Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 43, 1862-1873.
24. Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S, Vlodavsky I, and Nagler R (2006). Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia 8, 879-884.
25. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, and Vlodavsky I (2006). Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 8, 1055-1061.
26. Eldor A, Bar-Ner M, Yahalom J, Fuks Z, and Vlodavsky I (1987). Role of heparanase in platelet and tumor cell interactions with the subendothelial extracellular matrix. Semin Thromb Hemost 13, 475-488.
27. Ishai-Michaeli R, Eldor A, and Vlodavsky I (1990). Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Regul 1, 833-842.
28. Bar-Ner M, Kramer MD, Schirrmacher V, Ishai-Michaeli R, Fuks Z, and Vlodavsky I (1985). Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells. Int J Cancer 35, 483-491.
29. Nakajima M, Irimura T, DiFerrante D, DiFerrante N, and Nicolson GL (1983). Heparan sulfate degradation: relation to tumor invasion and metastatic properties of mouse B 16 melanoma sublines. Science 220, 611-613.
30. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, and Schirrmacher V (1983). Lymphoma cells mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relation to tumor cell metastasis. Cancer Res 43, 2704-2711.
31. Bitan M, Polliack A, Zecchina G, Nagler A, Friedmann Y, Nadav L, Deutsch V, Pecker I, Eldor A, Vlodavsky I, et al. (2002). Heparanase expression in human leukemias is restricted to acute myeloid leukemias. Exp Hematol 30, 34-41.
32. Miao HQ, Liu H, Navarro E, Kussie P, and Zhu Z (2006). Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 13, 2101-2111.
33. Sanderson RD, Yang Y, Suva LJ, and Kelly T (2004). Heparan sulfate proteoglycans and heparanase - partners in osteolytic tumor growth and metastasis. Matrix Biol 23, 341-352.
34. Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, Li C, Johnstone K, Karoli T, Davis K, Copeman E, et al. (2007). PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 33, 557-568.
35. Vlodavsky I, Abboud-Jarrous G, Elkin M, Naggi A, Casu B, Sasisekharan R, and Ilan N (2006). The impact of heparanase and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 35, 116-127.
36. Matzner Y, Bar-Ner M, Yahalom J, Ishai-Michaeli R, Fuks Z, and Vlodavsky I (1985). Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. J Clin Invest 76, 1306-1313.
37. Naparstek Y, Cohen IR, Fuks Z, and Vlodavsky I (1984). Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 310, 241-244.
38. Savion N, Disatnik MH, and Nevo Z (1987). Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells. J Cell Physiol 130, 77-84.
39. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR, and Fuks Z (1992). Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12, 112-127.
40. Sotnikov I, Hershkoviz R, Grabovsky V, Ilan N, Cahalon L, Vlodavsky I, Alon R, and Lider O (2004). Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol 172, 5185-5193.
41. Vaday GG and Lider O (2000). Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leukoc Biol 67, 149-159.
42. Ostrovsky O, Korostishevsky M, Levite I, Leiba M, Galski H, Vlodavsky I, and Nagler A (2007). Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia. [Epub July 5].
43. Nadir Y, Brenner B, Zetser A, Ilan N, Shafat I, Zcharia E, Goldshmidt O, and Vlodavsky I (2006). Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 4, 2443-2451.
44. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, and Ilan N (2004). Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 279, 23536-23541.
45. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, and Ilan N (2006). Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66, 1455-1463.
46. Zetser A, Bashenko Y, Miao HQ, Vlodavsky I, and Ilan N (2003). Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 63, 7733-7741.